1 min read
Add as a preferred source on GoogleSanofi Decides to Stop Studies of Nurix-Partnered Experimental Drug
Nurix Therapeutics shares extended losses from after Tuesday’s market close into Wednesday premarket trading.
Nurix Therapeutics said Tuesday that its partner Sanofi had decided to stop studies of an experimental inflammatory disease therapy.
NRIX shares entered Wednesday’s premarket session with losses from after the market closed Tuesday still in place.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.